Drug Trial Radar · NCT03006445
Study of FYU-981 in Hyperuricemia With or Without Gout
Last checked: Nov 19, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Dec 2016
Primary completion
Aug 23, 2018
Study completion Oct 24, 2018
Sponsor
- Lead sponsor
- Fuji Yakuhin Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Mochida Pharmaceutical Company, Ltd.
- First posted
- Dec 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is confirmatory investigation of safety and efficacy of FYU-981 administered orally to hyperuricemic patients with and without gout for 34 or 58 weeks by the method of multicenter, open label and ascending dose regimen.
Conditions
- Hyperuricemia With or Without Gout
Interventions
FYU-981Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent reduction from baseline in serum urate level at the final visitTime frame: 34 or 58 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.